Who is sponsoring NCT06304753?

NCT06304753 is sponsored by I.M. Sechenov First Moscow State Medical University.

What drugs are being tested in NCT06304753?

Interventions in NCT06304753: Telebot.

What condition does NCT06304753 study?

NCT06304753 studies Chronic Heart Failure With Low Ejection Fraction.

Is NCT06304753 still recruiting?

NCT06304753 is currently status unknown. Last updated 12 March 2024.

Last reviewed 2024-03-12 · How we verify

NCT06304753: BOT-IMPROVE-HF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ContriBution of Digital RemOte MoniToring to IMPROVing The Effectiveness of Treatment in Patients With Chronic Heart Failure With Low Ejection Fraction

Status unknown NA Last updated 12 March 2024

What this trial tests

NA trial testing Telebot in Chronic Heart Failure With Low Ejection Fraction in 60 participants. Status unknown.

Timeline

27 October 2023

Primary endpoint
1 July 2025

1 December 2025

Quick facts

Lead sponsor	I.M. Sechenov First Moscow State Medical University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	27 October 2023
Primary completion	1 July 2025
Estimated completion	1 December 2025
Sites	2 locations across Russia

Drugs / interventions tested

Telebot

Conditions studied

Chronic Heart Failure With Low Ejection Fraction — all drugs for Chronic Heart Failure With Low Ejection Fraction →

Sponsor

I.M. Sechenov First Moscow State Medical University

Who can join

Adults 18 to 85, any sex, with Chronic Heart Failure With Low Ejection Fraction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

BOT-IMPROVE-HF is a two-center, parallel group study designed to evaluate the efficacy of up-titration of heart failure treatment using digital remote monitoring after hospitalization due to heart failure decompensation. Patient will be randomized before discharge using a simple computer generated sequence to either remote monitoring or usual care group. Patients' condition in the "remote monitoring" arm will be assessed by mini-program based on a personal messenger and laboratory rests results will be asked by phone call. If these measures show safety and tolerability of the doses of the drugs, they will be increased to target or maximally tolerated doses. The follow-up period will be 6 months - 24 weeks. Patients of the usual care group will be followed by their general practitioner and/or cardiologist. All patients will be contacted after 6 months to assess outcomes.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Impact of Digital Remote Monitoring on the Optimization of Guideline-Directed Medical Therapy Titration in Heart Failure With Reduced Ejection Fraction.
Kozhevnikova MV, Emelianov AV, Zheleznykh EA, Pavlov NA, et al · · 2026 · PMID 41925172 · DOI 10.18087/cardio.2026.2.n3105
Bot-improve-hf: the potential of remote monitoring for rapid therapy optimization
· 2026

Verify or expand the search:

Other I.M. Sechenov First Moscow State Medical University trials

Trials by the same sponsor.

NCT07348991 — Predicting Severe Cardiac Arrhythmias in the Perioperative Period Using AI-ECG · not yet recruiting
NCT07412457 — Guideline Adherence in Dyslipidemia With Clinical Decision Support · not yet recruiting
NCT07396792 — Screening for Cardiac and Cardiac-associated Pathology Using Single-channel Electrocardiogram · not yet recruiting
NCT07412418 — Screening for Pulmonary Embolism Using Single-channel Electrocardiogram · not yet recruiting
NCT07518550 — Maternal and Fetal Electrocardiograms Separation Algorithm · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06304753 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by I.M. Sechenov First Moscow State Medical University
Last refreshed: 12 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06304753.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing